LUPIN2,074.00

Lupin Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMACIPLADRREDDYALKEMFORTISAUROPHARMALAURUSLABSMANKINDMcap ₹94,823 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation1,196.81,169.31,375.5
+ Finance Costs311.6294.9434.5
+ Interest Income-46.2-136.0-218.6
+ Fair Value (Gains) / Losses5.2-1.3-59.3
+ Share-based Payments38.342.339.0
+ Unrealised FX (Gain) / Loss-21.0-38.2-410.1
+ Other Non-cash Items12.812.363.9
+ Other — Cash Effects are Investing / Financing-30.8-41.7-129.2
Changes in Working Capital
+ Inventories-440.2-541.2-585.9
+ Trade Receivables — Current-240.8-780.9-738.8
+ Other Financial Assets — Current-112.4302.8-223.4
+ Other Financial Assets — Non-current10.5-29.45.3
+ Other Current Assets48.5-189.8-285.5
+ Other Non-current Assets32.3-0.514.7
+ Other Bank Balances-157.9-2,570.0211.1
+ Trade Payables — Current418.81.11,190.6
+ Other Financial Liabilities — Current42.986.4361.7
+ Other Financial Liabilities — Non-current25.5-41.10.9
+ Other Current Liabilities268.30.1505.3
+ Other Non-current Liabilities29.115.852.8
+ Provisions — Current9.0-250.8286.9
+ Provisions — Non-current-6.017.049.2
Cash from Operating Activities
Profit Before Tax (per I/S)2,422.34,015.06,872.67,474.4
+ Total Adjustments (incl. Working Capital)1,394.2-2,679.01,940.4
Cash from Operations (pre-tax)3,816.51,336.08,813.0
+ Income Taxes Paid326.1906.01,267.4
Cash from Operating Activities3,490.4429.97,545.6
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)928.91,682.42,054.9
+ Disp of Fixed Assets12.329.4247.7
+ Acq of Subsidiaries / Businesses (net)146.546.3135.8
+ Disp of Subsidiaries / Businesses (net)0.00.030.7
+ Interest Received — Investing46.2129.9216.9
+ Other Inflows / (Outflows) — Investing-537.4-32.4-2,380.4
Cash from Investing Activities-1,554.3-1,601.9-4,075.7
Cash from Financing Activities
+ Proceeds from Issue of Shares0.039.916.5
+ Proceeds from Exercise of Stock Options14.60.00.0
+ Proceeds from Borrowings0.02,427.7279.0
+ Repayment of Borrowings1,617.10.00.0
+ Payment of Lease Liabilities115.9140.9164.5
+ Interest Paid282.9229.5361.5
+ Dividends Paid182.8365.3548.3
+ Other Inflows / (Outflows) — Financing0.00.0-67.1
Cash from Financing Activities-2,184.21,731.9-845.9
Net Changes in Cash (pre-FX)-248.1559.92,624.0
Net Changes in Cash-248.1559.92,624.0
Closing Cash983.8
Reference Items
EBITDA3,810.55,283.38,816.09,538.3
EBITDA Margin %19.0423.2731.5331.83
Free Cash Flow (CFO − Capex)2,561.5-1,252.55,490.85,490.8
Free Cash Flow to Equity924.75,962.9
Free Cash Flow per Basic Share56.03-27.39120.10120.10
Price to Free Cash Flow17.27
Cash Flow to Net Income1.800.131.41
Cash Paid for Taxes326.1906.01,267.4
Cash Paid for Interest282.9229.5361.5
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.